The concurrent effect of succinate administration to protect against oxygen toxicity and of hyperbaric oxygen (HBO) exposures to treat model gas gangrene in mice was tested to determine whether succinate would interfere with the therapeutic efficacy of HBO. HBO (seven 90-min exposures) at 3 atmospheres absolute pressure (ATA) had been shown to reduce significantly the mortality of mice injected with Clostridium perfringens suspended in 10 ug of Adrenalin. When succinate was tested with this system, mortality of HBO-exposed infected animals was again significantly reduced (79% control mortality versus 17% HBO-exposed mortality), indicating that succinate does not interfere with the action of HBO. Exposures to 4 ATA of 02 were evaluated in the same model clostridial infection with succinate used to prevent oxygen toxicity. Five 30-min exposures at 4 ATA reduced the mortality of infected animals (62% control versus 6% HBO-exposed mortality). Intraperitoneal succinate injections (10 mmoles/kg) were given 20 to 25 min prior to four of the seven 3-ATA exposures and before three of the five 4-ATA exposures. The intermittent succinate injections gave significant protection against the development of oxygen toxicity in infected and noninfected mice at both 02 pressures. These studies support the potential clinical use of succinate or other oxygen-protective agents (i) to shorten HBO exposure times by using higher pressures to deliver the necessary 02 dose, (ii) to increase the 02 dose for difficult clinical situations by using maximal exposures at 4 ATA or more prolonged exposures at 2 to 3 ATA, and (iii) to continue HBO exposures in patients who require treatment but develop symptoms of oxygen toxicity.
Experimental and clinical data indicate that hyperbaric oxygen (HBO) is therapeutically valuable in treatment of gas gangrene (clostridial myonecrosis; 1, 3-6, 8-10, 16, 17) . The medical application of high pressures of oxygen is limited by the toxicity of oxygen, however, and short intermittent exposures are used to remain within a symptom-free latent period. Sanders and colleagues demonstrated that succinate injections significantly protect rats and dogs against the development of oxygen toxicity as measured by convulsion times and various biochemical parameters (13) (14) (15) . In the future, this protective agent may be used clinically to protect patients from possible adverse effects of high oxygen tensions. Since a primary medical use of HBO is for the treatment of gas gangrene, it is important to ascertain whether the concurrent administration of succinate might interfere with the action of HBO HBO. Mice were given oxygen exposures in a pressure chamber which possessed viewing ports and a temperature control device. The method of oxygen exposure has been described previously (6) . In the present studies, various HBO exposure schedules were tested ( (Fig. 1 ) was approximately the same as had been previously observed without the use of succinate (6) , and indicated that succinate injections did not interfere with HBO therapy of this infection.
A beinefit derived from the use of succinate was the total absence of oxygen toxicity symptoms among the HBO-exposed infected animals. In previous experiments (6) with HBO schedule A, central nervous system toxicity was observed in a few animals beginning at about the fifth HBO exposure. The seventh exposure was often shortened, or even deleted, to prevent severe oxygen damage when toxicity continued to develop. This toxicity was eliminated in the present series with the use of intermittent succinate injections.
Uninfected HBO control mice given succinate were compared to mice without succinate for t 100%02,3ATA,90min. symptoms of central nervous system toxicity in these controls were counted, 78% of the nonsuccinate HBO animals (25 of 32) showed toxicity compared to 24% of the succinate animals (6 of 25). The reactions ranged from a hyperexcited state which could be readily identified to severe grand mal-type convulsions. The nonsuccinate HBO control mice generally demonstrated toxic symptoms earlier (i.e., during the third, fourth, or fifth HBO exposure) and had more serious grand mal-type convulsions than the succinateinjected animals. The succinate-injected controls that showed toxic symptoms, in general, had mild symptoms such as hyperexcitability or short seizures without complete loss of consciousness. These symptoms began only during the final HBO exposures. Nine mice among the 32 nonsuccinate controls died, but no deaths occurred among the HBO control animals given succinate.
Succinate injections concurrent with HBO at 4 ATA for infection initiated with clostridia suspended in Adrenalin. On the basis of the results obtained when succinate was used in conjunction with HBO exposures at 3 ATA, the effect on clostridial infection of HBO at 4 ATA was tested.
Succinate injections were administered prior to HBO exposures 1, 3, and 4 on schedule B. To avoid oxygen toxicity, the number and duration of exposures were reduced. Again, a significant reduction in the mortality of infected mice given HBO exposures was observed (Fig. 2) . Protection from the development of oxygen toxicity was also apparent even though succinate was only used for three of five exposures. Only 23 % of the infected mice demonstrated mild symptoms of oxygen toxicity during the HBO exposures. Uninfected mice with and without succinate were again compared for their reactions in HBO. Protection from the development of oxygen toxicity followed the same general pattern as had been observed at 3 ATA. Noninfected mice given succinate had no or only mild symptoms of oxygen toxicity (two of seven), whereas the mice without succinate developed earlier and more severe symptoms (seven of seven).
Succinate injections concurrent with HBO at 4 ATA for infection initiated with clostridia suspended in calcium chloride. Exposures to 4 ATA of 02 were tested for control of the infection initiated with clostridia suspended in CaCl2. Mice with this model infection survived slightly longer than when the clostridia were given with Adrenalin, so three different exposure schedules were tested (schedules B, C, and D, Table 1 ). Succinate was injected prior to exposures 1, 3, and 4 for schedules B and C and only for exposures 1 and 3 on schedule D. With schedules B and C, no differences were observed between HBO-exposed and control infected mice insofar as survival time and overall mortality were concerned (Table 2 ). Schedule D appeared to be a better match between the delivery of HBO and the time course of the infection, but again no differences were found except in a single experiment. In one of four experiments, the HBOexposed mice had a significantly prolonged survival time compared to the infected controls (Kolmogorov-Smirnov statistical test, P > 0.01), but the overall mortality at 5 days was the same ( Table 2 ). The trials in which the mortality among infected control mice was higher than anticipated are included in Table 2 as additional information. Only a single infected mouse demonstrated mild symptoms of oxygen toxicity (1 of 110). Even though no generalized oxygen toxicity was encountered in the infected mice, there were indications (response after HBO exposure, mortality rates, and final mortality) that HBO might have had an added deleterious effect when given to mice already very toxic from advanced clostridial gangrene. Of 26 uninfected mice without succinate, 23 had central nervous system toxicity. This occasionally developed during the first HBO exposure, but usually began during the third or fourth exposure. Four of these mice died. Only one succinate-injected control (1 of 12) had mild symptoms of toxicity. On schedule D, the third succinate injection (given prior to exposure 4) could be deleted without development of oxygen toxicity in the infected mice. However, it was necessary to give the uninfected succinate controls the third injection, or they would develop oxygen toxicity. In this series, it was again observed that the infected mice showed less tendency to develop oxygen toxicity than the uninfected HBO control mice. 
DISCUSSION

